Expertise in
4
conditions

Dr. Raymond Brig

Oncology
Brig Center For Cancer Care And Survivorship
1400 Dowell Springs Blvd Ste 200, 
Knoxville, TN 
Expertise in
4
conditions
Brig Center For Cancer Care And Survivorship
1400 Dowell Springs Blvd Ste 200, 
Knoxville, TN 

Overview

Raymond Brig is an Oncologist in Knoxville, Tennessee. Dr. Brig is highly rated in 4 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in KY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Brig Center for Cancer Care and Survivorship
1400 Dowell Springs Blvd Ste 200, Knoxville, TN 37909

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

2 Total Publications

Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
Journal: Breast cancer (Tokyo, Japan)
Published: March 14, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Larry Kilgore
Oncology
Expertise in
19
conditions
Dr. Larry Kilgore
Oncology

Univ. Breast Center

1926 Alcoa Hwy Ste 410, 
Knoxville, TN 
 (9.0 miles away)
865-305-5622
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Larry Kilgore is an Oncologist in Knoxville, Tennessee. Dr. Kilgore is highly rated in 19 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Desmoplastic Small Round Cell Tumor, Ovarian Cancer, Ureteroscopy, and Oophorectomy.

Expertise in
19
conditions
Dr. Kristopher Kimball
Oncology
Expertise in
19
conditions
Dr. Kristopher Kimball
Oncology

University Of Tennessee Medical Center

1924 Alcoa Hwy, 
Knoxville, TN 
 (4.5 miles away)
865-305-6740
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kristopher Kimball is an Oncologist in Knoxville, Tennessee. Dr. Kimball is highly rated in 19 conditions, according to our data. His top areas of expertise are Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, Endometrial Cancer, Bladder Reconstruction, and Hysterectomy.

Expertise in
110
conditions
Dr. Daniel Ibach
Oncology
Expertise in
110
conditions
Dr. Daniel Ibach
Oncology

Tennessee Cancer Specialists PLLC

9957 Sherrill Blvd, 
Knoxville, TN 
 (5.8 miles away)
865-693-2255
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Ibach is an Oncologist in Knoxville, Tennessee. Dr. Ibach is highly rated in 110 conditions, according to our data. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Iron Deficiency Anemia, Breast Cancer, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Raymond Brig

How do I make an appointment with Dr. Raymond Brig?

You can book an appointment with Dr. Raymond Brig by calling their office at 865-246-1958. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Raymond Brig a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Raymond Brig is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Raymond Brig specialize in?

While Dr. Raymond Brig is a Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Raymond Brig participate in research or clinical trials?

Yes. Dr. Raymond Brig has published 2 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Raymond Brig's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brig's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile